MMF, Daclizumab and Corticosteroids as Mainstay Immunosuppression in Renal Transplant Patients
Status:
Completed
Trial end date:
2008-02-01
Target enrollment:
Participant gender:
Summary
To determine the renal function, as expressed by the glomerular filtration rate at 12 months,
in renal transplant recipients receiving mycophenolate mofetil, daclizumab, and
corticosteroids as mainstay immunosuppression in combination with low-dose cyclosporine,
tacrolimus, or sirolimus, and compare it to that of renal transplant recipients receiving
standard immunosuppression with mycophenolate mofetil, normal dose cyclosporine and
corticosteroids.